Orthovita to Participate in the RBC Capital Markets 2008 Healthcare Conference
Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery
company, announced today that it will participate in the RBC Capital
Markets 2008 Healthcare Conference in New York. Antony Koblish,
president and chief executive officer of Orthovita, will participate in
a panel discussion entitled "Showing Some Spine–With Innovation” on
Thursday, December 11th, at 11:00 a.m. Eastern Time, at The
Westin New York at Times Square, 270 West 43rd Street, New
York, NY. An audio-only webcast of the panel discussion will be
available and can be accessed for thirty days following the conference
by visiting http://www.wsw.com/webcast/rbc95/panel25.
About the Company
Orthovita is a spine and orthopedic biosurgery company with proprietary
biomaterials and biologic technologies for the development and
commercialization of synthetic, biologically active, tissue engineering
products. We develop and market synthetic-based biomaterials products
for use in spine surgery, the repair of fractures and a broad range of
clinical needs in the trauma, joint reconstruction, revision and
extremities markets. Our near-term commercial business is based on our
VITOSS® Bone Graft Substitute technology platforms, which are
designed to address the non-structural bone graft market by offering
synthetic alternatives to the use of autograft or cadaver-based bone
material, VITAGEL® Surgical Hemostat, which is an adherent
matrix and an impermeable barrier to blood flow, and VITASURE™
Absorbable Hemostat. Our longer-term U.S. clinical development program
is focused on our internally developed CORTOSS® Bone
Augmentation Material technology platform, which is primarily designed
for injections in osteoporotic spines to treat vertebral compression
fractures. We work jointly with Kensey Nash Corporation to develop and
commercialize certain products based on our VITOSS platform, we market
VITAGEL under a license agreement, we market VITASURE Absorbable
Hemostat under a distribution rights agreement, and we continue to
pursue similar relationships.
Disclosure Notice
This press release may contain forward-looking statements regarding
Orthovita’s current expectations of future events that involve risks and
uncertainties, including, without limitation, the development,
regulatory approval, demand and market acceptance of our products; our
ability to obtain FDA clearance for CORTOSS in the United States; and
other aspects of our business.
Such statements are based on
management’s current expectations and are subject to a number of
substantial risks and uncertainties that could cause actual results or
timeliness to differ materially from those addressed in the
forward-looking statements.
Other factors that may cause such a
difference are listed from time to time in reports filed by the Company
with the U.S. Securities and Exchange Commission (SEC), including but
not limited to risks described in our most recently filed Form 10-K
under the caption "Risks Factors”.
Further information about
these and other relevant risks and uncertainties may be found in
Orthovita’s filings with the SEC, all of which are available from the
SEC as well as other sources. Orthovita undertakes no obligation to
publicly update any forward-looking statements.
